{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T02:54:26Z","timestamp":1791428066899,"version":"4.3.3"},"reference-count":23,"publisher":"American Medical Association (AMA)","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"abstract":"\n Importance<\/jats:title>\n Risk stratification in advanced mycosis fungoides and S\u00e9zary syndrome (MF\/SS) remains suboptimal given that current TNMB (tumor, node, metastasis, blood) staging has limited prognostic value for clinically relevant outcomes.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To determine whether the Cutaneous Lymphoma International Prognostic Index (CLIPI) may be used to predict progression-free survival (PFS) and best objective response (BOR) in patients with advanced MF\/SS.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This international prospective cohort study included patients with stage IIB to IVB MF\/SS from the PROCLIPI trial which ran from July 1, 2015, to May 1, 2025, across 46 referral centers. Median follow-up was 4.75 (95% CI, 4.04-5.13) years; eligible participants had complete data on CLIPI, PFS, and BOR. Data were analyzed from September 1 to December 1, 2025.<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n CLIPI score at diagnosis, based on age (&amp;gt;60 years), elevated serum lactate dehydrogenase, N3 nodal status, and large-cell transformation in the skin. Patients were classified as having low (0 or 1 factor), intermediate (2 factors), or high risk (3 or 4 factors).<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n PFS (defined as diagnosis to disease progression or death) and BOR (complete response, partial response, stable disease, or progressive disease) during follow-up. Exploratory analyses evaluated treatment effects before progression using inverse probability weighting.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Among 277 patients (median [IQR] age at diagnosis, 66 [23-89] years; 183 male individuals [65.7%]), 144 (52.0%) were classified as having low risk, 93 (33.6%) intermediate risk, and 40 (14.4%) high risk. They had a median PFS of 4.64 years (95% CI, 3.50-5.76), 2.72 years (95% CI, 1.81-4.56), and 0.89 years (95% CI, 0.65-1.14), respectively (log-rank\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001). Patients in the intermediate-risk (hazard ratio [HR], 1.45; 95% CI, 1.01-2.08) and high-risk (HR, 3.84; 95% CI, 2.21-6.66) CLIPI groups displayed higher hazards of progression or death than those at low risk. Inclusion of CLIPI improved PFS discrimination over a model with baseline stage alone. Each 1-point increase in CLIPI was associated with\u2009approximately\u200938% lower odds of observing a better response during follow-up (odds ratio, 0.62; 95% CI, 0.43-0.89).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this international prospective cohort of patients with advanced MF\/SS, CLIPI scores were associated with risk of disease progression and likelihood of response beyond clinical stage. These findings indicate that CLIPI may help to refine risk stratification and support its integration into clinical decision-making and future trial design.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamadermatol.2026.3856","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T15:00:22Z","timestamp":1791385222000},"source":"Crossref","is-referenced-by-count":1,"title":["Cutaneous Lymphoma International Prognostic Index and Risk Stratification in Advanced Mycosis Fungoides and S\u00e9zary Syndrome"],"prefix":"10.1001","author":[{"given":"Gabriele","family":"Roccuzzo","sequence":"first","affiliation":[{"name":"Department of Medical Sciences, Section of Dermatology, University of Turin, Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham","family":"Bashir","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospitals Birmingham NHS Foundation Trust & University of Birmingham, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicity","family":"Evison","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospitals Birmingham NHS Foundation Trust & University of Birmingham, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Whittaker","sequence":"additional","affiliation":[{"name":"St Johns Institute of Dermatology, King\u2019s College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Bagot","sequence":"additional","affiliation":[{"name":"H\u00f4pital Saint Louis, Universit\u00e9 Paris Cit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuella","family":"Guenova","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital Zurich and Faculty of Medicine, University of Zurich, Zurich, Switzerland"},{"name":"University Department of Dermatology, University of Lausanne and Lausanne University Hospital, Lausanne, Switzerland"},{"name":"Department of Immunodermatology, Kepler University Hospital and Medical Faculty, Johannes Kepler University, Linz, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelia","family":"Papadavid","sequence":"additional","affiliation":[{"name":"Department of Dermatology-Venereology, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry Miles","family":"Prince","sequence":"additional","affiliation":[{"name":"Sir Peter McCallum Department of Oncology, University of Melbourne and Epworth Healthcare, Monash University, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose A.","family":"Sanches","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of S\u00e3o Paulo Medical School, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis R.","family":"Miyashiro","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of S\u00e3o Paulo Medical School, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Octavio","family":"Servitje","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital Universitari de Bellvitge, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Querfeld","sequence":"additional","affiliation":[{"name":"City of Hope Comprehensive Cancer Center and Beckman Research Institute, Duarte, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oleg","family":"Akilov","sequence":"additional","affiliation":[{"name":"University of Pittsburgh School of Medicine, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arvind","family":"Arumainathan","sequence":"additional","affiliation":[{"name":"The Clatterbridge Cancer Centre, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Bennett","sequence":"additional","affiliation":[{"name":"University Hospital Southampton, Southampton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Battistella","sequence":"additional","affiliation":[{"name":"Pathology department, H\u00f4pital Saint-Louis, AP-HP, Universit\u00e9 Paris Cit\u00e9, INSERM U1342, Institut de Recherche Saint-Louis, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Bayne","sequence":"additional","affiliation":[{"name":"Gloucestershire Hospitals NHS Foundation Trust, Gloucester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Alberti Violetti","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, Department of Pathophysiology and Transplantation, Universit\u00e0 Degli Studi di Milano, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Fava","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Section of Dermatology, University of Turin, Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Iselin","sequence":"additional","affiliation":[{"name":"University Department of Dermatology, University of Lausanne and Lausanne University Hospital, Lausanne, Switzerland"},{"name":"Department of Immunodermatology, Kepler University Hospital and Medical Faculty, Johannes Kepler University, Linz, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Beylot-Barry","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University and Hospital of Bordeaux, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Marie","family":"Busschots","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Cowan","sequence":"additional","affiliation":[{"name":"The Christie Hospital, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"Dummer","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital Z\u00fcrich and University Z\u00fcrich, Z\u00fcrich and Kantonsspital Aarau, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giles","family":"Dunnill","sequence":"additional","affiliation":[{"name":"Bristol Royal Infirmary, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Estrach","sequence":"additional","affiliation":[{"name":"Hospital Clinic, University of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larisa","family":"Geskin","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Columbia University Irving Medical Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro A.","family":"Gru","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Columbia University Irving Medical Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Guitart","sequence":"additional","affiliation":[{"name":"Departments of Dermatology and Pathology, Northwestern University, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melba C.","family":"Herrera","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Stanford University School of Medicine, Palo Alto, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmilia","family":"Hodak","sequence":"additional","affiliation":[{"name":"Cutaneous Lymphoma Clinic, Davidoff Cancer Center, Beilinson Hospital, Tel Aviv University, Rabin Medical Center, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Horwitz","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering, Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constanze","family":"Jonak","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus-Detlev","family":"Klemke","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Akademisches Lehrkrankenhaus der Universit\u00e4t Freiburg, Karlsruhe, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Knobler","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pam","family":"Mckay","sequence":"additional","affiliation":[{"name":"Beatson West of Scotland Cancer Center, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Marschalk\u00f3","sequence":"additional","affiliation":[{"name":"Department of Dermatovenereology Semmelweis Medical University, Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesare","family":"Massone","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Galliera Hospital, Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rubeta N.","family":"Matin","sequence":"additional","affiliation":[{"name":"Oxford University Hospitals NHS Foundation Trust, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Mitteldorf","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology and Allergology, University Medical Center G\u00f6ttingen, G\u00f6ttingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Novoa","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Stanford University School of Medicine, Palo Alto, California"},{"name":"Department of Pathology, Stanford University School of Medicine, Palo Alto, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Ortiz-Romero","sequence":"additional","affiliation":[{"name":"Dermatology Department, Institute i+12, Hospital 12 de Octubre, Medical School, University Complutense, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Pimpinelli","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, Dermatology Unit, University of Florence, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramon M.","family":"Pujol","sequence":"additional","affiliation":[{"name":"Dermatology Department, Hospital del Mar, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerri E.","family":"Rieger","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Stanford University School of Medicine, Palo Alto, California"},{"name":"Department of Pathology, Stanford University School of Medicine, Palo Alto, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf","family":"Stadler","sequence":"additional","affiliation":[{"name":"Cutaneous Lymphoma Centre, Department of Dermatology, Johannes Wesling Medical Centre, University Hospitals of the Ruhr University of Bochum, Minden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franz","family":"Trautinger","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, University Hospital of St P\u00f6lten, Karl Landsteiner University of Health Sciences, St P\u00f6lten, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Latzka","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, University Hospital of St P\u00f6lten, Karl Landsteiner University of Health Sciences, St P\u00f6lten, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten","family":"Vermeer","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Leiden University Medical Center, Leiden, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Wachsmuth","sequence":"additional","affiliation":[{"name":"Royal Devon Healthcare and Taunton and Somerset NHS Foundation Trust, Exeter, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Weatherhead","sequence":"additional","affiliation":[{"name":"Newcastle Upon Tyne NHS Trust, Newcastle, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Wehkamp","sequence":"additional","affiliation":[{"name":"Medical Department, Medical School Hamburg, Hamburg, Germany"},{"name":"Medical Development, Helios Kliniken, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Wobser","sequence":"additional","affiliation":[{"name":"Deparment of Dermatology, Venereology and Allergology, University Hospital Wuerzburg, Wuerzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Quaglino","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Section of Dermatology, University of Turin, Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youn H.","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Stanford University School of Medicine, Palo Alto, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Scarisbrick","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospitals Birmingham NHS Foundation Trust & University of Birmingham, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,10,7]]},"reference":[{"issue":"16","key":"doi260046r1","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1182\/blood-2018-11-881268","article-title":"The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas.","volume":"133","author":"Willemze","year":"2019","journal-title":"Blood"},{"key":"doi260046r2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.113343","article-title":"EORTC consensus recommendations for the treatment of mycosis fungoides\/S\u00e9zary syndrome-Update 2023.","volume":"195","author":"Latzka","year":"2023","journal-title":"Eur J Cancer"},{"issue":"5","key":"doi260046r3","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1182\/blood.2021012057","article-title":"Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC.","volume":"140","author":"Olsen","year":"2022","journal-title":"Blood"},{"issue":"21","key":"doi260046r4","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1182\/blood.V124.21.1621.1621","article-title":"A Cutaneous Lymphoma International Consortium \u2018CLIC\u2019 study of prognostic parameters in advanced stages of mycosis fungoides and Sezary syndrome: progress towards establishing a prognostic index to augment clinical staging.","volume":"124","author":"Scarisbrick","year":"2014","journal-title":"Blood"},{"key":"doi260046r5","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ejca.2018.01.076","article-title":"Blood classification and blood response criteria in mycosis fungoides and S\u00e9zary syndrome using flow cytometry: recommendations from the EORTC cutaneous lymphoma task force.","volume":"93","author":"Scarisbrick","year":"2018","journal-title":"Eur J Cancer"},{"issue":"14","key":"doi260046r6","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1182\/blood.2025029628","article-title":"A new prognostic index (CLIPI) for advanced cutaneous lymphoma enables precise patient risk stratification.","volume":"146","author":"Scarisbrick","year":"2025","journal-title":"Blood"},{"issue":"32","key":"doi260046r7","doi-asserted-by":"publisher","first-page":"3766","DOI":"10.1200\/JCO.2015.61.7142","article-title":"Cutaneous Lymphoma International Consortium Study of outcome in advanced stages of mycosis fungoides and S\u00e9zary syndrome: effect of specific prognostic markers on survival and development of a prognostic model.","volume":"33","author":"Scarisbrick","year":"2015","journal-title":"J Clin Oncol"},{"issue":"1","key":"doi260046r8","doi-asserted-by":"publisher","DOI":"10.1016\/j.lpm.2022.104123","article-title":"The PROCLIPI international registry, an important tool to evaluate the prognosis of cutaneous T cell lymphomas.","volume":"51","author":"Scarisbrick","year":"2022","journal-title":"Presse Med"},{"issue":"10094","key":"doi260046r9","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/S0140-6736(17)31266-7","article-title":"Brentuximab vedotin or physician\u2019s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial.","volume":"390","author":"Prince","year":"2017","journal-title":"Lancet"},{"issue":"9","key":"doi260046r10","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/S1470-2045(18)30379-6","article-title":"Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet Oncol"},{"key":"doi260046r11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115484","article-title":"Phase II trial of atezolizumab (Anti-PD-L1) in the treatment of relapsed\/refractory IIB\/IVB mycosis fungoides\/S\u00e9zary syndrome patients after previous systemic treatment. EORTC-1652-CLTG \u201cPARCT\u201d.","volume":"222","author":"Stadler","year":"2025","journal-title":"Eur J Cancer"},{"issue":"2","key":"doi260046r12","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1111\/bjd.17258","article-title":"The PROCLIPI international registry of early-stage mycosis fungoides identifies substantial diagnostic delay in most patients.","volume":"181","author":"Scarisbrick","year":"2019","journal-title":"Br J Dermatol"},{"issue":"3","key":"doi260046r14","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1093\/annonc\/mdy207","article-title":"Global patterns of care in advanced stage mycosis fungoides\/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium.","volume":"30","author":"Quaglino","year":"2019","journal-title":"Ann Oncol"},{"issue":"12","key":"doi260046r16","doi-asserted-by":"publisher","first-page":"E491","DOI":"10.1002\/ajh.24564","article-title":"A retrospective comparative outcome analysis following systemic therapy in Mycosis fungoides and Sezary syndrome.","volume":"91","author":"Hanel","year":"2016","journal-title":"Am J Hematol"},{"issue":"7","key":"doi260046r17","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1182\/blood-2011-08-376319","article-title":"Prognostic factors in transformed mycosis fungoides: a retrospective analysis of 100 cases.","volume":"119","author":"Benner","year":"2012","journal-title":"Blood"},{"issue":"3","key":"doi260046r18","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1111\/bjh.20225","article-title":"Large-cell transformation of mycosis fungoides: patterns of care and patient outcomes.","volume":"207","author":"Johnstone","year":"2025","journal-title":"Br J Haematol"},{"issue":"4","key":"doi260046r19","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1182\/blood.V92.4.1150","article-title":"Transformation of mycosis fungoides\/Sezary syndrome: clinical characteristics and prognosis.","volume":"92","author":"Diamandidou","year":"1998","journal-title":"Blood"},{"issue":"4","key":"doi260046r20","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1111\/bjh.70051","article-title":"Lymph node detection of monoclonal T-cell population correlates with poorer prognosis in mycosis fungoides and S\u00e8zary syndrome.","volume":"207","author":"Miyashiro","year":"2025","journal-title":"Br J Haematol"},{"issue":"7","key":"doi260046r21","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1080\/14656566.2024.2360646","article-title":"Advances in the pharmacological management of cutaneous T-cell lymphoma.","volume":"25","author":"Roccuzzo","year":"2024","journal-title":"Expert Opin Pharmacother"},{"issue":"5","key":"doi260046r22","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1111\/bjh.19647","article-title":"Improving disease-specific survival for patients with Sezary syndrome in the modern era of systemic therapies.","volume":"205","author":"Campbell","year":"2024","journal-title":"Br J Haematol"},{"issue":"10392","key":"doi260046r23","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1016\/S0140-6736(23)00329-X","article-title":"Allogeneic transplantation in advanced cutaneous T-cell lymphomas (CUTALLO): a propensity score matched controlled prospective study.","volume":"401","author":"de Masson","year":"2023","journal-title":"Lancet"},{"key":"doi260046r13","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-030-16399-0","volume-title":"Clinical Prediction Models: A Practical Approach to Development, Validation, and Updating","author":"Steyerberg","year":"2019"},{"key":"doi260046r15","volume-title":"Stata 19 Causal Inference and Treatment-Effects Estimation Reference Manual","author":"StataCorp","year":"2025"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2854943\/jamadermatology_roccuzzo_2026_oi_260046_1791216041.0782.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T15:00:23Z","timestamp":1791385223000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2854943"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,7]]},"references-count":23,"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2026.3856","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10,7]]}}}